Treatment of acromegaly improves quality of life, measured by AcroQol.
AuthorsPaisley, Angela N
Rowles, Susannah V
Roberts, Margaret E
Webb, Susan M
Shalet, Stephen M
Trainer, Peter J
AffiliationDepartment of Endocrinology, Christie Hospital, Wilmslow Road, Manchester, UK.
MetadataShow full item record
AbstractBACKGROUND: AcroQol is a disease-generated questionnaire, developed to assess quality of life (QOL) in patients with acromegaly. We have previously demonstrated severely impaired QOL in patients with acromegaly and the value of AcroQol in measuring QOL in a cross-sectional study compared with the non-disease-specific generic tools 'Psychological general wellbeing schedule' (PGWBS) and EuroQol (EQ-5D), and the disease-specific signs and symptoms score (SSS). AIM, SUBJECTS AND METHODS: We re-evaluated these tools in a longitudinal study of 56 of the previously reported patients (33 male, mean age 55 +/- 15 years), in order to determine change in QOL over time and the effect of different treatment modalities. Data were analysed using Spearman's correlation tests. RESULTS: Baseline median IGF-I was 354 ng/ml (range 48-899) and at re-evaluation 217 ng/ml (60-594) (P < 0.001) [median time interval 608 days (113-1136)]. Analysis of change in IGF-I levels and AcroQol scores demonstrated a significant negative correlation (i.e. a reduction in IGF-I being associated with improved overall QOL (r = -0.36, P = 0.006). Significant negative correlations were also seen in the physical (r = -0.33, P = 0.01), psychological (r = -0.37, P = 0.005) and appearance (r = -0.42, P = 0.001) AcroQol subdomains. No correlations were seen between change in IGF-I and change in overall PGWBS score or subdomains, SSS or EQ-5D. CONCLUSIONS: In summary, of the tools studied we have demonstrated AcroQol to be uniquely capable of detecting changes in QOL associated with treatment-induced improvement in the main biochemical marker of disease activity in patients with acromegaly. Further studies are required to evaluate the long-term biological significance of the changes seen in AcroQol.
CitationTreatment of acromegaly improves quality of life, measured by AcroQol. 2007, 67 (3):358-62 Clin. Endocrinol.
- Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire.
- Authors: Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ
- Issue date: 2005 Jun
- Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.
- Authors: Chin SO, Chung CH, Chung YS, Kim BJ, Kim HY, Kim IJ, Kim JG, Kim MS, Kim SY, Lee EJ, Lee KY, Kim SW
- Issue date: 2015 Jun 10
- Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study.
- Authors: Webb SM, Badia X, Surinach NL, Spanish AcroQol Study Group.
- Issue date: 2006 Aug
- Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study.
- Authors: Kyriakakis N, Lynch J, Gilbey SG, Webb SM, Murray RD
- Issue date: 2017 Jun
- Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly.
- Authors: T'Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R
- Issue date: 2007 Oct